Disney
DIS
Adobe
ADBE
Taiwan Semiconductor
TSM
4
Alibaba
BABA
5
Meta Platforms
META
US Stock MarketDetailed Quotes
IBIO iBio Inc
- 1.320
- +0.270+25.71%
Trading Apr 29 12:39 ET
13.29MMarket Cap0.77P/E (TTM)
1.620High1.050Low10.69MVolume1.060Open1.050Pre Close14.82MTurnover121.51%Turnover RatioLossP/E (Static)10.07MShares6.89152wk High0.96P/B11.61MFloat Cap0.63652wk Low--Dividend TTM8.79MShs Float30300.000Historical High--Div YieldTTM54.29%Amplitude0.636Historical Low1.387Avg Price1Lot Size
iBio Inc Stock Forum
Sign in to post a comment
3
4
$iBio Inc (IBIO.US)$
Revolutionary AI-Discovered Obesity Drug: iBio Licenses First-Ever Activin E Antibody in $28M Deal
Revolutionary AI-Discovered Obesity Drug: iBio Licenses First-Ever Activin E Antibody in $28M Deal
$iBio Inc (IBIO.US)$
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Tuesday, 22nd April at 8:00 am
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting Activin E, which was discovered using iBio's patented Machine-Learning Antibody Engine. Activin ...
iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio
Tuesday, 22nd April at 8:00 am
SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Bio, Inc. (NASDAQ: IBIO), an AI-driven innovator of precision antibody therapies, today announced a licensing agreement with AstralBio Inc. for a preclinical first-in-class antibody targeting Activin E, which was discovered using iBio's patented Machine-Learning Antibody Engine. Activin ...
$iBio Inc (IBIO.US)$
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Monday, 7th April at 7:00 am
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days
Additional interim in vivo data for a first-in-class Activin E anti...
iBio Announces IBIO-600 Non-Human Primate Data Showing Extended Half-Life and Muscle Growth, and Interim In Vivo Results for First-in-Class Activin E Antibody, Advancing Cardiometabolic and Obesity Pipeline
Monday, 7th April at 7:00 am
Non-human primate pharmacokinetics data suggests IBIO-600, a potentially best-in-class long-acting anti-myostatin antibody, could have a human half-life as long as 130 days
Additional interim in vivo data for a first-in-class Activin E anti...
1
1
$iBio Inc (IBIO.US)$ lmfao can't believe this is still listed
$iBio Inc (IBIO.US)$ great hands play this kottos to you all
$iBio Inc (IBIO.US)$ strong hands have this one
1
$iBio Inc (IBIO.US)$ its ready again
$iBio Inc (IBIO.US)$ needs more eyes on it
No comment yet
Market Insights
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
70107480 : What is your method?
TheMasterMind OP 70107480 : basically if there is a day with a bullish green candle on the daily, with an outlier day of 5-10x normal volume (fat green volume candle on the bottom) you buy towards the days close or early premarket on the RSI dips into oversold that day. The next morning almost always shorts will cover their previous days shorts and you can make 10-50% every morning. Basically whole point is monitoring the 5min and daily candle and having extreme volume
TheMasterMind OP : you gotta take the volume into context though, so typically the first day when a stock does that, definitely buy it, like what WW did last friday. My original buys were at .36-.37 cents. I stupidly swung trade into and out and now dont have that good an average
TheMasterMind OP : anything on the top gainers list that has a green daily candle i look at with an outlier day of volume. Pretty simple